In fact, the link between Rb loss and resistance to steroid hormone deprivation therapy may extend beyond prostate cancer with Rb mutations found to be associated with resistance to estrogen deprivation in estrogen receptor-positive breast cancer [35,36]. Here, RB1 is linked to prostate carcinoma.